Van Rompaey Nicolas, Le Moine Alain
Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Methods Mol Biol. 2011;677:169-80. doi: 10.1007/978-1-60761-869-0_12.
CD11b+GR1+ myeloid-derived suppressor cells (MDSC) accumulate in several inflammatory conditions including cancer, infections, or trauma. MDSCs are found in bone marrow and lymphoid organs and suppress both innate and adaptive immune responses. Although mechanisms of suppression are not fully understood, they have been reported to require cell-cell contact and very often implicate L-arginine metabolism. We and others recently observed that lipopolysaccharide (LPS) administration, as other TLR ligands, induces MDSC. In this case, MDSC regulate immune response independently of L-arginine metabolism through heme oxygenase-1 activity. Manipulating MDSC as immunoregulators represents an attractive approach for cancer immunotherapy or transplantation. Herein, we describe methods for expanding and purifying MDSC, as well as in vitro and in vivo techniques to measure their suppressive functions.
CD11b+GR1+髓源性抑制细胞(MDSC)在包括癌症、感染或创伤在内的多种炎症状态下会积聚。MDSC存在于骨髓和淋巴器官中,可抑制先天性和适应性免疫反应。尽管抑制机制尚未完全明确,但据报道其需要细胞间接触,且常常涉及L-精氨酸代谢。我们和其他人最近观察到,与其他Toll样受体(TLR)配体一样,给予脂多糖(LPS)可诱导MDSC产生。在这种情况下,MDSC通过血红素加氧酶-1的活性独立于L-精氨酸代谢来调节免疫反应。将MDSC作为免疫调节剂进行操控,对于癌症免疫治疗或移植而言是一种有吸引力的方法。在此,我们描述了扩增和纯化MDSC的方法,以及测量其抑制功能的体外和体内技术。